کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8456693 | 1548740 | 2018 | 43 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Genetic markers a landscape in prostate cancer
ترجمه فارسی عنوان
نشانگرهای ژنتیکی چشم انداز در سرطان پروستات است
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ADTmetastatic CRPCHK2BEAMingCirculating free DNAmCRPCCRPCddPCRMMRAREsPSAMPCPHIcfDNACTCDHTCNVPFs - PF هاProstate specific antigen - آنتی ژن اختصاصی پروستاتprogression-free survival - بقا بدون پیشرفتoverall survival - بقای کلBiomarker - بیومارکرTumor biopsy - بیوپسی تومورLiquid biopsy - بیوپسی مایعmismatch repair - تعمیر ناسازگاریcopy number variation - تنوع نسخه کپیandrogen deprivation therapy - درمان اندروژن محرومیتDihydrotestosterone - دی هیدروتستوسترونProstate cancer - سرطان پروستاتMetastatic prostate cancer - سرطان پروستات متاستاتیکCastration resistant prostate cancer - سرطان پروستات مقاوم در برابر کاتتراسیونProstate health index - شاخص سلامت پروستاتAndrogen response elements - عناصر پاسخ اندروژنScreening - غربالگریphosphatase and tensin homolog - فسفاتاز و تنسین همولوگodds ratio - نسبت شانس هاpolymerase chain reaction - واکنش زنجیره ای پلیمرازPCR - واکنش زنجیرهٔ پلیمرازSingle nucleotide polymorphism - پلیمورفیسم تک نوکلئوتیدیSNP - چندریختی تک-نوکلئوتیدPten - ژن PTENkilobase - کیلوبایزcirculating tumor cell - گردش سلول تومورAndrogen Receptor - گیرنده آندروژنی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
چکیده انگلیسی
Prostate cancer (PC) is one of the most common cancers worldwide. The observed variability in progression and responses to the same treatment between patients underlie the genetic heterogeneity of the disease. Nowadays, screening and follow-up biomarkers in PC are still having a deep lack of information, which makes difficult the cancer diagnosis, prognosis and the selection of the most suitable therapies. This is making that currently unnecessary biopsies, over-treatments and hormonoresistances have high rates of prevalence among patients. New biomarkers are urgently needed and in this sense genomic biomarkers could be the most suitable tools. These genetic markers will be helpful for improving the precision of prognostic and the predictive current tools which are employed in the clinical practice. A recent literature search up was conducted, including clinical trials and pre-clinical basic research studies. Keywords included germline variants, prostate cancer, biomarkers, androgen deprivation therapy, screening and liquid biopsy; among others. We have reviewed how germline variants, CNVs and repetitive regions are relevant to prostate carcinogenesis, treatment and progression. Moreover, we have also considered novel biomarkers for PC prognosis based on differentially expressed genes. Finally, we have included new strategies in recent markers of liquid biopsy or updated technologies for minimal samples analysis. The improvement of genetic markers use and their application to the clinical practice, will enhance the variability of simple, non-invasive, tools such as liquid biopsy and germline variants, these will reduce the number of PC needle biopsies and current over-treatments that are usual in the management of this cancer.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mutation Research/Reviews in Mutation Research - Volume 775, JanuaryâMarch 2018, Pages 1-10
Journal: Mutation Research/Reviews in Mutation Research - Volume 775, JanuaryâMarch 2018, Pages 1-10
نویسندگان
J.M. Cozar, I. Robles-Fernandez, L.J. Martinez-Gonzalez, M. Pascual-Geler, Alba Rodriguez-Martinez, M.J. Serrano, J.A. Lorente, M.J. Alvarez-Cubero,